Pasar al contenido principal

FUNCION DE LA VIA DE NOTCH EN LA ADQUISION DEL POTENCIAL DE CELULA MADRE HEMATOPOYETICA, HETEROGENEIDAD Y LATENCIA (NOTCH-HETHSC)

PID2019-104695RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT HOSPITAL DEL MAR D'INVESTIGACIONS MEDIQUES

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

β-Catenin activity induces an RNA biosynthesis program promoting therapy resistance in T-cell acute lymphoblastic leukemia

  • García Hernández, Violeta
  • Arambilet, David
  • Guillén, Yolanda
  • Lobo-Jarne, Teresa
  • Maqueda, Maria
  • Gekas, Christos
  • González, Jessica
  • Iglesias, Arnau
  • Vega García, Nerea
  • Sentís Carreras, Inés 1990-
  • Trincado Alonso, Juan Luis, 1987-
  • Márquez-López, Ian
  • Heyn, Holger
  • Camós, Mireia
  • Espinosa Blay, Lluís
  • Bigas Salvans, Anna
Understanding the molecular mechanisms that contribute to the appearance of chemotherapy resistant cell populations is necessary to improve cancer treatment. We have now investigated the role of β-catenin/CTNNB1 in the evolution of T-cell Acute Lymphoblastic Leukemia (T-ALL) patients and its involvement in therapy resistance. We have identified a specific gene signature that is directly regulated by β-catenin, TCF/LEF factors and ZBTB33/Kaiso in T-ALL cell lines, which is highly and significantly represented in five out of six refractory patients from a cohort of 40 children with T-ALL. By subsequent refinement of this gene signature, we found that a subset of β-catenin target genes involved with RNA-processing function are sufficient to segregate T-ALL refractory patients in three independent cohorts. We demonstrate the implication of β-catenin in RNA and protein synthesis in T-ALL and provide in vitro and in vivo experimental evidence that β-catenin is crucial for the cellular response to chemotherapy, mainly in the cellular recovery phase after treatment. We propose that combination treatments involving chemotherapy plus β-catenin inhibitors will enhance chemotherapy response and prevent disease relapse in T-ALL patients., This work has been funded by Agencia Estatal de Investigación (SAF2016-75613-R and PID2019-104695RB-I00), Fundación AECC (GC16173697BIGA) and WCR (13-0064). VGH, DA and TL are recipients of Sara Borrell fellowship from ISCIII co-funded by the ESF+ (CD21/00145), FPI (BES-2017-080880) and AECC fellowship (POSTD21975LOBO), respectively.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate

  • Thambyrajah, Roshana
  • Maqueda, Maria
  • Neo, Wen Hao
  • Imbach, Kathleen
  • Guillén, Yolanda
  • Grases, Daniela
  • Fadlullah, Zaki
  • Gambera, Stefano
  • Matteini, Francesca
  • Wang, Xiaonan
  • Calero-Nieto, Fernando J.
  • Esteller, Manel
  • Florian, Maria Carolina
  • Porta-Pardo, Eduard
  • Benedito, Rui
  • Göttgens, Berthold
  • Lacaud, Georges
  • Espinosa Blay, Lluís
  • Bigas Salvans, Anna
Hematopoietic stem cells (HSCs) develop from the hemogenic endothelium (HE) in the aorta- gonads-and mesonephros (AGM) region and reside within Intra-aortic hematopoietic clusters (IAHC) along with hematopoietic progenitors (HPC). The signalling mechanisms that distinguish HSCs from HPCs are unknown. Notch signaling is essential for arterial specification, IAHC formation and HSC activity, but current studies on how Notch segregates these different fates are inconsistent. We now demonstrate that Notch activity is highest in a subset of, GFI1 + , HSC-primed HE cells, and is gradually lost with HSC maturation. We uncover that the HSC phenotype is maintained due to increasing levels of NOTCH1 and JAG1 interactions on the surface of the same cell (cis) that renders the NOTCH1 receptor from being activated. Forced activation of the NOTCH1 receptor in IAHC activates a hematopoietic differentiation program. Our results indicate that NOTCH1-JAG1 cis-inhibition preserves the HSC phenotype in the hematopoietic clusters of the embryonic aorta., We thank Sarah Bray and David Sprinzak for critical discussions about cis interactions. We thank Genentech for kindly gifting the anti-JAG1 and anti-NOTCH1 antibodies. We thank all members of Espinosa and Bigas laboratories for helpful discussions and technical support. All illustrations in the manuscript were created with BioRender.com. We also thank the animal facility, FACS facility, and genomic facility of the PRBB and CRUK Manchester Institute for their technical support. This work was funded by grants from SAF2016-75613-R and PID2019-104695RB-I00 from Agencia Estatal de Investigación (AEI) and SLT002/16/00299 from Department of Health, Generalitat de Cataluña and 2021 SGR 00039 from AGAUR, Generalitat de Catalunya. The work in the G.L. laboratory is supported by Blood Cancer UK (19014) and Cancer Research UK Manchester Institute Core Grant (C5759/A27412). The work in R.B. laboratory was supported by a grant from the Ministerio de Ciencia e Innovación (MCIN - PID2020-120252RB-I00). RT is a recipient of BP2016 (00021) and BP/MSCA 2018 (00034) fellowship programs from Generalitat de Catalunya/MSCA. E.P. is a recipient of RYC2019-026415-I. M.M. is a recipient of a grant from the Instituto Carlos III, grant number CA22/00011 (cofunded by the European Social Fund Plus, ESF+, and by the European Union).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dynamic chromatin association of IκBα is regulated by acetylation and cleavage of histone H4

  • Marruecos, Laura
  • Bertran, Joan
  • Álvarez-Villanueva, Daniel
  • Mulero, María Carmen
  • Guillén, Yolanda
  • Palma, Luis G.
  • Floor, Martin
  • Vert, Anna
  • Arce-Gallego, Sara
  • Pecharroman, Irene
  • Batlle Masó, Laura, 1993-
  • Villà i Freixa, Jordi
  • Ghosh, Gourisankar
  • Bigas Salvans, Anna
  • Espinosa Blay, Lluís
IκBs exert principal functions as cytoplasmic inhibitors of NF-kB transcription factors. Additional roles for IκB homologues have been described, including chromatin association and transcriptional regulation. Phosphorylated and SUMOylated IκBα (pS-IκBα) binds to histones H2A and H4 in the stem cell and progenitor cell compartment of skin and intestine, but the mechanisms controlling its recruitment to chromatin are largely unknown. Here, we show that serine 32-36 phosphorylation of IκBα favors its binding to nucleosomes and demonstrate that p-IκBα association with H4 depends on the acetylation of specific H4 lysine residues. The N-terminal tail of H4 is removed during intestinal cell differentiation by proteolytic cleavage by trypsin or chymotrypsin at residues 17-19, which reduces p-IκBα binding. Inhibition of trypsin and chymotrypsin activity in HT29 cells increases p-IκBα chromatin binding but, paradoxically, impaired goblet cell differentiation, comparable to IκBα deletion. Taken together, our results indicate that dynamic binding of IκBα to chromatin is a requirement for intestinal cell differentiation and provide a molecular basis for the understanding of the restricted nuclear distribution of p-IκBα in specific stem cell compartments., We want to thank the Bigas’ and Espinosa’s lab members for constructive discussions and suggestions and technical support. This work has been funded by Instituto de Salud Carlos III FEDER (PI19/0013), Agencia Estatal de Investigación, Spain (PID2019-104695RB-I00) to A.B., NIH/GM085490 to G.G., BIO2017-83650-P to JVF and Generalitat de Catalunya 2017SGR135. LM is a predoctoral fellow of 2015FI-B00806 and 2016FI-B1 00110 and MF has financial support by the Universitat de Vic-Universitat Central de Catalunya PhD fellowships program. The authors thankfully acknowledge the computer resources at Pirineus and the technical support provided by the Spanish Supercomputer Network (BCV-2020-1-0001).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development

  • Thambyrajah, Roshana
  • Maqueda, Maria
  • Fadlullah, Zaki
  • Proffitt, Martin
  • Neo, Wen Hao
  • Guillén, Yolanda
  • Casado-Peláez, Marta
  • Herrero-Molinero, Patricia
  • Brujas, Carla
  • Castelluccio, Noemi
  • González, Jessica
  • Iglesias, Arnau
  • Marruecos, Laura
  • Ruiz-Herguido, Cristina
  • Esteller, Manel
  • Mereu, Elisabetta
  • Lacaud, Georges
  • Espinosa Blay, Lluís
  • Bigas Salvans, Anna
Recent findings suggest that Hematopoietic Stem Cells (HSC) and progenitors arise simultaneously and independently of each other already in the embryonic aorta-gonad mesonephros region, but it is still unknown how their different features are established. Here, we uncover IκBα (Nfkbia, the inhibitor of NF-κB) as a critical regulator of HSC proliferation throughout development. IκBα balances retinoic acid signaling levels together with the epigenetic silencer, PRC2, specifically in HSCs. Loss of IκBα decreases proliferation of HSC and induces a dormancy related gene expression signature instead. Also, IκBα deficient HSCs respond with superior activation to in vitro culture and in serial transplantation. At the molecular level, chromatin regions harboring binding motifs for retinoic acid signaling are hypo-methylated for the PRC2 dependent H3K27me3 mark in IκBα deficient HSCs. Overall, we show that the proliferation index in the developing HSCs is regulated by a IκBα-PRC2 axis, which controls retinoic acid signaling., This work was funded by grants from SAF2016-75613-R, PID2019-104695RB-I00, and PDC2021-120817-I00 from Agencia Estatal de Investigación (AEI) and SLT002/16/00299 from Department of Health, Generalitat de Catalunya. The work in G.L. laboratory is supported by Blood Cancer UK (19014) and Cancer Research UK Manchester Institute Core Grant (C5759/A27412). R.T. is a recipient of BP2016(00021) and BP/MSCA 2018(00034) fellowship programs from Generalitat de Catalunya/MSCA. M.M. is a recipient of a grant from the Instituto Carlos III, grant number CA22/00011 (co-funded by the European Social Fund Plus, ESF+, and by the European Union).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Using pluripotent stem cells to understand normal and leukemic hematopoietic development

  • Bigas Salvans, Anna
  • Galán i Palma, Luis
  • Kartha, Gayathri M.
  • Giorgetti, Alessandra
Several decades have passed since the generation of the first embryonic stem cell (ESC) lines both in mice and in humans. Since then, stem cell biologists have tried to understand their potential biological and clinical uses for their implementation in regenerative medicine. The hematopoietic field was a pioneer in establishing the potential use for the development of blood cell products and clinical applications; however, early expectations have been truncated by the difficulty in generating bonafide hematopoietic stem cells (HSCs). Despite some progress in understanding the origin of HSCs during embryonic development, the reproduction of this process in vitro is still not possible, but the knowledge acquired in the embryo is slowly being implemented for mouse and human pluripotent stem cells (PSCs). In contrast, ESC-derived hematopoietic cells may recapitulate some leukemic transformation processes when exposed to oncogenic drivers. This would be especially useful to model prenatal leukemia development or other leukemia-predisposing syndromes, which are difficult to study. In this review, we will review the state of the art of the use of PSCs as a model for hematopoietic and leukemia development., This work was funded by grants from PID2019-104695RB-I00 and PDC2021-120817-I00from AgenciaEstatal de Investigación (AEI) to AB, ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció instrumental de SLT011/18/00006 and SLT011/18/00007 of the Department of Health of the Government of Catalonia to AG and A, the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO PID2020-15591RB-100), La Marató de TV3 (202001-32) and CERCA Programme/Generalitat de Catalunya for institutional support to AG. LGP is a recipient of 2021 FI_B2 00188, AGAUR, Generalitat de Cataluña.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo-Campos, M. A.
  • Lutfi, Nuria
  • Bonnin, S.
  • Martínez, C.
  • Velasco-Hernández, Talia
  • García-Hernández, V.
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, R.
  • Colomo, L.
  • Roué, Gaël
  • Guilbaud, G.
  • Dantzer, Françoise
  • Navarro Medrano, Pilar
  • Murga, Matilde
  • Fernández-Capetillo, Óscar
  • Bigas, A.
  • Menéndez, Pablo
  • Sale; J. E.
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the E¿-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic E¿-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors., The J.Y. laboratory is funded by the Spanish Ministerio de Economía, Industria y Competitividad (grant SAF2017-83565-R), Spanish Ministerio de Ciencia e Innovación (grant PID2020-112526RB-I00), and Fundación Científica de la Asociación Española Contra el Cáncer (grant PROYEI6018YÉLA). Work in the J.E.S. laboratory is supported by a core grant to the Laboratory of Molecular Biology from the Medical Research Council (U105178808). The F.D. laboratory is supported by a Laboratory of Excellence grant (ANR-10-LABX-0034_Medalis) to Strasbourg University, Centre National de la Recherche Scientifique. The P.N. laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness/Instituto de Salud Carlos III–Fondo Europeo de Desarrollo Regional (FEDER; PI17/00199 and PI20/00625) and the Generalitat de Catalunya (2017-SGR-225). The P.M. laboratory acknowledges support from Centres de Recerca de Catalunya/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the Spanish Ministry of Economy and Competitiveness (grant SAF-2019-108160-R), the Fundación Uno entre Cienmil, the Obra Social La Caixa (grant LCF/PR/HR19/52160011), and the German Josep Carreras Leukamie Stiftung. Work at the G.R. and P.M. laboratories are cofinanced by the European Regional Development Fund through the Interreg V-A Spain-France-Andorra Program (project PROTEOblood; grant EFA360/19). The O.F.-C. laboratory is funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTI2018-102204-B-I00; cofinanced with European FEDER funds) and the European Research Council (ERC-617840). T.V.-H. was supported by a Marie Sklodowska Curie fellowship (GA792923). The A.B. laboratory is supported by the Spanish Ministry of Economy and Competitiveness (grant PID2019-104695RB-I00)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate

  • Thambyrajah, Roshana
  • Maqueda, Maria
  • Neo, Wen Hao
  • Imbach, Kathleen
  • Guillén, Yolanda
  • Grases, Daniela
  • Fadlullah, Zaki
  • Gambera, Stefano
  • Matteini, Francesca
  • Wang, Xiaonan
  • Calero-Nieto, Fernando J.
  • Esteller, Manel
  • Florian, Maria Carolina
  • Porta-Pardo, Eduard
  • Benedito, Rui
  • Göttgens, Berthold
  • Lacaud, Georges
  • Espinosa Blay, Lluís
  • Bigas Salvans, Anna
Hematopoietic stem cells (HSCs) develop from the hemogenic endothelium (HE) in the aorta- gonads-and mesonephros (AGM) region and reside within Intra-aortic hematopoietic clusters (IAHC) along with hematopoietic progenitors (HPC). The signalling mechanisms that distinguish HSCs from HPCs are unknown. Notch signaling is essential for arterial specification, IAHC formation and HSC activity, but current studies on how Notch segregates these different fates are inconsistent. We now demonstrate that Notch activity is highest in a subset of, GFI1 + , HSC-primed HE cells, and is gradually lost with HSC maturation. We uncover that the HSC phenotype is maintained due to increasing levels of NOTCH1 and JAG1 interactions on the surface of the same cell (cis) that renders the NOTCH1 receptor from being activated. Forced activation of the NOTCH1 receptor in IAHC activates a hematopoietic differentiation program. Our results indicate that NOTCH1-JAG1 cis-inhibition preserves the HSC phenotype in the hematopoietic clusters of the embryonic aorta., We thank Sarah Bray and David Sprinzak for critical discussions about cis interactions. We thank Genentech for kindly gifting the anti-JAG1 and anti-NOTCH1 antibodies. We thank all members of Espinosa and Bigas laboratories for helpful discussions and technical support. All illustrations in the manuscript were created with BioRender.com. We also thank the animal facility, FACS facility, and genomic facility of the PRBB and CRUK Manchester Institute for their technical support. This work was funded by grants from SAF2016-75613-R and PID2019-104695RB-I00 from Agencia Estatal de Investigación (AEI) and SLT002/16/00299 from Department of Health, Generalitat de Cataluña and 2021 SGR 00039 from AGAUR, Generalitat de Catalunya. The work in the G.L. laboratory is supported by Blood Cancer UK (19014) and Cancer Research UK Manchester Institute Core Grant (C5759/A27412). The work in R.B. laboratory was supported by a grant from the Ministerio de Ciencia e Innovación (MCIN - PID2020-120252RB-I00). RT is a recipient of BP2016 (00021) and BP/MSCA 2018 (00034) fellowship programs from Generalitat de Catalunya/MSCA. E.P. is a recipient of RYC2019-026415-I. M.M. is a recipient of a grant from the Instituto Carlos III, grant number CA22/00011 (cofunded by the European Social Fund Plus, ESF+, and by the European Union).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development

  • Thambyrajah, Roshana
  • Maqueda, Maria
  • Fadlullah, Zaki
  • Proffitt, Martin
  • Neo, Wen Hao
  • Guillén, Yolanda
  • Casado-Peláez, Marta
  • Herrero-Molinero, Patricia
  • Brujas, Carla
  • Castelluccio, Noemi
  • González, Jessica
  • Iglesias, Arnau
  • Marruecos, Laura
  • Ruiz-Herguido, Cristina
  • Esteller, Manel
  • Mereu, Elisabetta
  • Lacaud, Georges
  • Espinosa Blay, Lluís
  • Bigas Salvans, Anna
Recent findings suggest that Hematopoietic Stem Cells (HSC) and progenitors arise simultaneously and independently of each other already in the embryonic aorta-gonad mesonephros region, but it is still unknown how their different features are established. Here, we uncover IκBα (Nfkbia, the inhibitor of NF-κB) as a critical regulator of HSC proliferation throughout development. IκBα balances retinoic acid signaling levels together with the epigenetic silencer, PRC2, specifically in HSCs. Loss of IκBα decreases proliferation of HSC and induces a dormancy related gene expression signature instead. Also, IκBα deficient HSCs respond with superior activation to in vitro culture and in serial transplantation. At the molecular level, chromatin regions harboring binding motifs for retinoic acid signaling are hypo-methylated for the PRC2 dependent H3K27me3 mark in IκBα deficient HSCs. Overall, we show that the proliferation index in the developing HSCs is regulated by a IκBα-PRC2 axis, which controls retinoic acid signaling., This work was funded by grants from SAF2016-75613-R, PID2019-104695RB-I00, and PDC2021-120817-I00 from Agencia Estatal de Investigación (AEI) and SLT002/16/00299 from Department of Health, Generalitat de Catalunya. The work in G.L. laboratory is supported by Blood Cancer UK (19014) and Cancer Research UK Manchester Institute Core Grant (C5759/A27412). R.T. is a recipient of BP2016(00021) and BP/MSCA 2018(00034) fellowship programs from Generalitat de Catalunya/MSCA. M.M. is a recipient of a grant from the Instituto Carlos III, grant number CA22/00011 (co-funded by the European Social Fund Plus, ESF+, and by the European Union).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

β-Catenin activity induces an RNA biosynthesis program promoting therapy resistance in T-cell acute lymphoblastic leukemia

  • García Hernández, Violeta
  • Arambilet, David
  • Guillén, Yolanda
  • Lobo-Jarne, Teresa
  • Maqueda, Maria
  • Gekas, Christos
  • González, Jessica
  • Iglesias, Arnau
  • Vega García, Nerea
  • Sentís Carreras, Inés 1990-
  • Trincado Alonso, Juan Luis, 1987-
  • Márquez-López, Ian
  • Heyn, Holger
  • Camós, Mireia
  • Espinosa Blay, Lluís
  • Bigas Salvans, Anna
Understanding the molecular mechanisms that contribute to the appearance of chemotherapy resistant cell populations is necessary to improve cancer treatment. We have now investigated the role of β-catenin/CTNNB1 in the evolution of T-cell Acute Lymphoblastic Leukemia (T-ALL) patients and its involvement in therapy resistance. We have identified a specific gene signature that is directly regulated by β-catenin, TCF/LEF factors and ZBTB33/Kaiso in T-ALL cell lines, which is highly and significantly represented in five out of six refractory patients from a cohort of 40 children with T-ALL. By subsequent refinement of this gene signature, we found that a subset of β-catenin target genes involved with RNA-processing function are sufficient to segregate T-ALL refractory patients in three independent cohorts. We demonstrate the implication of β-catenin in RNA and protein synthesis in T-ALL and provide in vitro and in vivo experimental evidence that β-catenin is crucial for the cellular response to chemotherapy, mainly in the cellular recovery phase after treatment. We propose that combination treatments involving chemotherapy plus β-catenin inhibitors will enhance chemotherapy response and prevent disease relapse in T-ALL patients., This work has been funded by Agencia Estatal de Investigación (SAF2016-75613-R and PID2019-104695RB-I00), Fundación AECC (GC16173697BIGA) and WCR (13-0064). VGH, DA and TL are recipients of Sara Borrell fellowship from ISCIII co-funded by the ESF+ (CD21/00145), FPI (BES-2017-080880) and AECC fellowship (POSTD21975LOBO), respectively.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Using pluripotent stem cells to understand normal and leukemic hematopoietic development

  • Bigas Salvans, Anna
  • Galán i Palma, Luis
  • Kartha, Gayathri M.
  • Giorgetti, Alessandra
Several decades have passed since the generation of the first embryonic stem cell (ESC) lines both in mice and in humans. Since then, stem cell biologists have tried to understand their potential biological and clinical uses for their implementation in regenerative medicine. The hematopoietic field was a pioneer in establishing the potential use for the development of blood cell products and clinical applications; however, early expectations have been truncated by the difficulty in generating bonafide hematopoietic stem cells (HSCs). Despite some progress in understanding the origin of HSCs during embryonic development, the reproduction of this process in vitro is still not possible, but the knowledge acquired in the embryo is slowly being implemented for mouse and human pluripotent stem cells (PSCs). In contrast, ESC-derived hematopoietic cells may recapitulate some leukemic transformation processes when exposed to oncogenic drivers. This would be especially useful to model prenatal leukemia development or other leukemia-predisposing syndromes, which are difficult to study. In this review, we will review the state of the art of the use of PSCs as a model for hematopoietic and leukemia development., This work was funded by grants from PID2019-104695RB-I00 and PDC2021-120817-I00from AgenciaEstatal de Investigación (AEI) to AB, ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció instrumental de SLT011/18/00006 and SLT011/18/00007 of the Department of Health of the Government of Catalonia to AG and A, the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO PID2020-15591RB-100), La Marató de TV3 (202001-32) and CERCA Programme/Generalitat de Catalunya for institutional support to AG. LGP is a recipient of 2021 FI_B2 00188, AGAUR, Generalitat de Cataluña.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dynamic chromatin association of IκBα is regulated by acetylation and cleavage of histone H4

  • Marruecos, Laura
  • Bertran, Joan
  • Álvarez-Villanueva, Daniel
  • Mulero, María Carmen
  • Guillén, Yolanda
  • Palma, Luis G.
  • Floor, Martin
  • Vert, Anna
  • Arce-Gallego, Sara
  • Pecharroman, Irene
  • Batlle Masó, Laura, 1993-
  • Villà i Freixa, Jordi
  • Ghosh, Gourisankar
  • Bigas Salvans, Anna
  • Espinosa Blay, Lluís
IκBs exert principal functions as cytoplasmic inhibitors of NF-kB transcription factors. Additional roles for IκB homologues have been described, including chromatin association and transcriptional regulation. Phosphorylated and SUMOylated IκBα (pS-IκBα) binds to histones H2A and H4 in the stem cell and progenitor cell compartment of skin and intestine, but the mechanisms controlling its recruitment to chromatin are largely unknown. Here, we show that serine 32-36 phosphorylation of IκBα favors its binding to nucleosomes and demonstrate that p-IκBα association with H4 depends on the acetylation of specific H4 lysine residues. The N-terminal tail of H4 is removed during intestinal cell differentiation by proteolytic cleavage by trypsin or chymotrypsin at residues 17-19, which reduces p-IκBα binding. Inhibition of trypsin and chymotrypsin activity in HT29 cells increases p-IκBα chromatin binding but, paradoxically, impaired goblet cell differentiation, comparable to IκBα deletion. Taken together, our results indicate that dynamic binding of IκBα to chromatin is a requirement for intestinal cell differentiation and provide a molecular basis for the understanding of the restricted nuclear distribution of p-IκBα in specific stem cell compartments., We want to thank the Bigas’ and Espinosa’s lab members for constructive discussions and suggestions and technical support. This work has been funded by Instituto de Salud Carlos III FEDER (PI19/0013), Agencia Estatal de Investigación, Spain (PID2019-104695RB-I00) to A.B., NIH/GM085490 to G.G., BIO2017-83650-P to JVF and Generalitat de Catalunya 2017SGR135. LM is a predoctoral fellow of 2015FI-B00806 and 2016FI-B1 00110 and MF has financial support by the Universitat de Vic-Universitat Central de Catalunya PhD fellowships program. The authors thankfully acknowledge the computer resources at Pirineus and the technical support provided by the Spanish Supercomputer Network (BCV-2020-1-0001).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo Campos, Miguel A.|||0000-0002-0650-8660
  • Lutfi, Nura
  • Bonnin, Sarah|||0000-0001-5159-2518
  • Martínez Cáceres, Carlos|||0000-0003-3307-1326
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • García-Hernández, Violeta|||0000-0003-2328-4360
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, Ramón|||0000-0002-8758-121X
  • Colomo, Luis|||0000-0001-5236-5085
  • Roué, Gaël|||0000-0003-0245-2257
  • Guilbaud, Guillaume|||0000-0002-4345-6855
  • Dantzer, Françoise
  • Navarro, Pilar|||0000-0003-4314-4584
  • Murga, Matilde|||0000-0002-9766-4481
  • Fernández Capetillo, Oscar|||0000-0002-2690-6885
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Sale, Julian E.
  • Yélamos, José|||0000-0003-1195-1496
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the Eμ-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic Eμ-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

β-Catenin activity induces an RNA biosynthesis program promoting therapy resistance in T-cell acute lymphoblastic leukemia

  • García-Hernández, Violeta|||0000-0003-2328-4360
  • Arambilet Mobilla, David|||0000-0001-7372-0082
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Maqueda, Maria|||0000-0001-9304-1714
  • Gekas, Christos|||0000-0002-3429-4145
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Iglesias, Arnau|||0000-0002-7195-7868
  • Vega-García, Nerea
  • Sentís, Inés|||0000-0001-8320-9579
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Márquez-López, Ian
  • Heyn, Holger|||0000-0002-3276-1889
  • Camós, Mireia|||0000-0003-3658-7942
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Bigas Salvans, Anna|||0000-0003-4801-6899
Understanding the molecular mechanisms that contribute to the appearance of chemotherapy resistant cell populations is necessary to improve cancer treatment. We have now investigated the role of β-catenin/CTNNB1 in the evolution of T-cell Acute Lymphoblastic Leukemia (T-ALL) patients and its involvement in therapy resistance. We have identified a specific gene signature that is directly regulated by β-catenin, TCF/LEF factors and ZBTB33/Kaiso in T-ALL cell lines, which is highly and significantly represented in five out of six refractory patients from a cohort of 40 children with T-ALL. By subsequent refinement of this gene signature, we found that a subset of β-catenin target genes involved with RNA-processing function are sufficient to segregate T-ALL refractory patients in three independent cohorts. We demonstrate the implication of β-catenin in RNA and protein synthesis in T-ALL and provide in vitro and in vivo experimental evidence that β-catenin is crucial for the cellular response to chemotherapy, mainly in the cellular recovery phase after treatment. We propose that combination treatments involving chemotherapy plus β-catenin inhibitors will enhance chemotherapy response and prevent disease relapse in T-ALL patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Recent advances in T-cell lymphoid neoplasms

  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Rodriguez-Sevilla, Juan José
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Gallardo, Fernando|||0000-0002-8996-3828
T Cells comprise many subtypes of specified lymphocytes, and their differentiation and function take place in different tissues. This cellular diversity is also observed in the multiple ways T-cell transformation gives rise to a variety of T-cell neoplasms. This review covers the main types of T-cell malignancies and their specific characteristics, emphasizing recent advances at the cellular and molecular levels as well as differences and commonalities among them.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development

  • Thambyrajah, Roshana|||0000-0002-3941-760X
  • Maqueda, Maria|||0000-0001-9304-1714
  • Fadlullah, Muhammad Zaki|||0000-0002-3111-8090
  • Proffitt, Martin
  • Neo, Wen Hao|||0000-0002-6827-3027
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Casado Pelaez, Marta|||0000-0002-8428-8384
  • Herrero-Molinero, Patricia
  • Brujas, Carla
  • Castelluccio, Noemi|||0000-0003-2635-4889
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Iglesias, Arnau|||0000-0002-7195-7868
  • Marruecos, Laura|||0000-0002-4206-709X
  • Ruiz-Herguido, Cristina
  • Esteller, M|||0000-0003-4490-6093
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Lacaud, Georges|||0000-0002-5630-2417
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Bigas Salvans, Anna|||0000-0003-4801-6899
Recent findings suggest that Hematopoietic Stem Cells (HSC) and progenitors arise simultaneously and independently of each other already in the embryonic aorta-gonad mesonephros region, but it is still unknown how their different features are established. Here, we uncover IκBα (Nfkbia, the inhibitor of NF-κB) as a critical regulator of HSC proliferation throughout development. IκBα balances retinoic acid signaling levels together with the epigenetic silencer, PRC2, specifically in HSCs. Loss of IκBα decreases proliferation of HSC and induces a dormancy related gene expression signature instead. Also, IκBα deficient HSCs respond with superior activation to in vitro culture and in serial transplantation. At the molecular level, chromatin regions harboring binding motifs for retinoic acid signaling are hypo-methylated for the PRC2 dependent H3K27me3 mark in IκBα deficient HSCs. Overall, we show that the proliferation index in the developing HSCs is regulated by a IκBα-PRC2 axis, which controls retinoic acid signaling.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate

  • Thambyrajah, Roshana|||0000-0002-3941-760X
  • Maqueda, Maria|||0000-0001-9304-1714
  • Neo, Wen Hao|||0000-0002-6827-3027
  • Imbach, Kathleen|||0000-0002-3861-7845
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Grases Mendoza, Daniela|||0000-0002-5981-7248
  • Fadlullah, Zaki
  • Gambera, Stefano|||0000-0003-2998-8502
  • Matteini, Fernando
  • Wang, Xiaonan|||0000-0003-3759-778X
  • Calero-Nieto, Fernando|||0000-0003-3358-8253
  • Esteller, M.|||0000-0003-4490-6093
  • Florian, María Carolina
  • Porta-Pardo, Eduard|||0000-0001-7900-4239
  • Benedito, Rui|||0000-0003-2458-3055
  • Göttgens, Berthold|||0000-0001-6302-5705
  • Lacaud, Georges|||0000-0002-5630-2417
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Bigas Salvans, Anna|||0000-0003-4801-6899
Hematopoietic stem cells (HSCs) develop from the hemogenic endothelium (HE) in the aorta- gonads-and mesonephros (AGM) region and reside within Intra-aortic hematopoietic clusters (IAHC) along with hematopoietic progenitors (HPC). The signalling mechanisms that distinguish HSCs from HPCs are unknown. Notch signaling is essential for arterial specification, IAHC formation and HSC activity, but current studies on how Notch segregates these different fates are inconsistent. We now demonstrate that Notch activity is highest in a subset of, GFI1 +, HSC-primed HE cells, and is gradually lost with HSC maturation. We uncover that the HSC phenotype is maintained due to increasing levels of NOTCH1 and JAG1 interactions on the surface of the same cell (cis) that renders the NOTCH1 receptor from being activated. Forced activation of the NOTCH1 receptor in IAHC activates a hematopoietic differentiation program. Our results indicate that NOTCH1-JAG1 cis-inhibition preserves the HSC phenotype in the hematopoietic clusters of the embryonic aorta.